Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 3;2(1):vdaa076. doi: 10.1093/noajnl/vdaa076

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — At the initial presentation, MRI revealed a mass at the cervicomedullary junction measuring 2 × 2.5 × 2.3 cm (A and B). After subtotal surgical resection (C and D), the size of the hemangioblastoma decreased to 1.6 × 0.6 × 1.1 cm. With 10 months of surveillance, the hemangioblastoma increased to 1.6 × 1.0 × 1.4 cm (E and F). There was an enlargement of the hemangioblastoma 1-month (mo) post-stereotactic radiosurgery, measuring 1.9 × 1.5 × 1.8 cm, with associated edema and hydrocephalus (G and H). Ongoing surveillance revealed a further increase of the hemangioblastoma (2.0 × 1.8 × 2.0 cm) and increased surrounding edema (I and J). After bevacizumab therapy, there was a decrease in the size of the hemangioblastoma, measuring 1.4 × 1.5 × 1.7 cm (K and L) and reduction of surrounding edema. Over 1 year of clinical surveillance, the hemangioblastoma has remained stable in size, measuring 1.4 × 1.6 × 1.7 cm (M and N).